本文選題：胃癌前狀態(tài) + 血清學(xué)指標(biāo)��； 參考：《安徽醫(yī)科大學(xué)學(xué)報(bào)》2017年10期

【摘要】：目的探討血清胃蛋白酶原(PG)、促胃液素-17(G-17)和幽門螺桿菌抗體對(duì)胃癌前狀態(tài)的診斷效能。方法收集331例慢性胃炎患者,觀察胃黏膜萎縮、腸化、上皮內(nèi)瘤變以及不同OLGA/OLGIM分期患者的血清PG和G-17水平的變化以及ABC法各組中胃癌前狀態(tài)的發(fā)病情況。結(jié)果 (1)胃竇萎縮患者的血清G-17水平低于無(wú)萎縮(P=0.030),胃體萎縮患者的血清PGⅠ/PGⅡ比值(PGR)水平低于無(wú)萎縮(P=0.046),全胃萎縮患者的血清PGⅠ(P=0.036)及PGR(P=0.030)水平低于無(wú)萎縮;(2)胃竇腸化患者的血清G-17水平低于無(wú)腸化(P=0.021),全胃腸化患者的血清PGⅠ水平低于無(wú)腸化(P=0.015);(3)全胃低級(jí)別上皮內(nèi)瘤變患者的血清PGⅠ水平低于無(wú)低級(jí)別上皮內(nèi)瘤變(P=0.036);(4)OLGA分期中血清PGⅠ水平隨分期嚴(yán)重程度加重逐漸降低,以Ⅳ期降低明顯(P=0.035);(5)OLGIM分期中血清PGⅠ水平隨分期嚴(yán)重程度的加重逐漸降低,以Ⅳ期降低明顯(P=0.018);(6)"ABC法"分組中,盡管高危組中發(fā)生胃癌前狀態(tài)的患者占組內(nèi)人數(shù)的比例較低危組高,但低危組中仍有50.16%的患者為慢性萎縮性胃炎以及15.96%的患者為低級(jí)別上皮內(nèi)瘤變。結(jié)論血清PG和G-17可以作為胃癌前狀態(tài)發(fā)生風(fēng)險(xiǎn)的臨床篩查指標(biāo),ABC法對(duì)早期胃癌具有篩查作用,但低危組人群仍存在發(fā)生胃癌前狀態(tài)的風(fēng)險(xiǎn)。
[Abstract]:Objective to investigate the diagnostic efficacy of serum pepsinogen PGN, gastrin-17 G-17) and Helicobacter pylori antibody in pregastric cancer. Methods the changes of serum PG and G-17 levels in 331 patients with chronic gastritis, including gastric mucosal atrophy, intestinal metaplasia, intraepithelial neoplasia and different OLGA/OLGIM stages, as well as the precancerous state of gastric cancer in the ABC group were observed. Results (1) the serum G-17 level in patients with antral atrophy was lower than that in patients without atrophic antrum (P 0.030), the serum PG 鈪，

本文編號(hào)：1832671